• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?

作者信息

Younossi Zobair

机构信息

Center for Liver Diseases, Department of Medicine Inova Fairfax Hospital Falls Church VA.

Betty and Guy Beatty Center for Integrated Research Inova Health System Falls Church VA.

出版信息

Clin Liver Dis (Hoboken). 2015 Dec 9;6(5):117-119. doi: 10.1002/cld.509. eCollection 2015 Nov.

DOI:10.1002/cld.509
PMID:31041004
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6490666/
Abstract
摘要

相似文献

1
What is the ethical responsibility of a provider when prescribing the new direct-acting antiviral agents to patients with hepatitis C infection?在为丙型肝炎感染患者开新型直接抗病毒药物时，医疗服务提供者的伦理责任是什么？
Clin Liver Dis (Hoboken). 2015 Dec 9;6(5):117-119. doi: 10.1002/cld.509. eCollection 2015 Nov.
2
Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.美国丙型肝炎病毒感染全口服直接抗病毒药物的初始吸收率、治疗时间和真实世界疗效：一项回顾性队列分析。
PLoS One. 2019 Aug 22;14(8):e0218759. doi: 10.1371/journal.pone.0218759. eCollection 2019.
3
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.终末期肾病患者使用丙型肝炎病毒直接抗病毒药物的“真实世界”经验。
Int J Artif Organs. 2018 Jul;41(7):363-370. doi: 10.1177/0391398818763478. Epub 2018 Mar 27.
4
[Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].直接作用抗病毒药物治疗慢性丙型肝炎病毒感染患者的有效性和安全性
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):175-178. doi: 10.3760/cma.j.issn.1007-3418.2018.03.004.
5
Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.一家葡萄牙中心的经验：丙型肝炎直接抗病毒治疗的有效性
Acta Med Port. 2019 Mar 29;32(3):189-194. doi: 10.20344/amp.10655.
6
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
7
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.丙型肝炎病毒相关性肾小球疾病的免疫抑制和抗病毒治疗：长期随访
Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.
8
[Selection of direct-acting antiviral agents for chronic hepatitis C infection].[慢性丙型肝炎感染直接抗病毒药物的选择]
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):169-172. doi: 10.3760/cma.j.issn.1007-3418.2018.03.002.
9
Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents.在直接作用抗病毒药物时代，基于他汀类药物（3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂）治疗丙型肝炎病毒（HCV）感染相关疾病
F1000Res. 2016 Feb 26;5:223. doi: 10.12688/f1000research.7970.3. eCollection 2016.
10
[Consensus on management of drug-drug interaction with direct-acting antiviral agents in chronic hepatitis C].[慢性丙型肝炎中直接作用抗病毒药物药物相互作用管理的共识]
Zhonghua Gan Zang Bing Za Zhi. 2018 Jul 20;26(7):481-488. doi: 10.3760/cma.j.issn.1007-3418.2018.07.001.

引用本文的文献

1
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.非酒精性脂肪性肝病、非酒精性脂肪性肝炎及相关纤维化的诊断方法。
Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721.

本文引用的文献

1
Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?丙型肝炎病毒治疗：是否有可能治愈所有丙型肝炎病毒患者？
Clin Gastroenterol Hepatol. 2015 Nov;13(12):2166-72. doi: 10.1016/j.cgh.2015.07.015. Epub 2015 Jul 17.
2
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.聚乙二醇干扰素α-2a 联合利巴韦林治疗慢性丙型肝炎的病毒学应答预测因素分析
J Hepatol. 2015 Aug;63(2):337-45. doi: 10.1016/j.jhep.2015.03.014. Epub 2015 Mar 17.
3
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.丙型肝炎病毒新型抗病毒治疗的成本效益、健康效益及财务成本。
Clin Infect Dis. 2015 Jul 15;61(2):157-68. doi: 10.1093/cid/civ220. Epub 2015 Mar 16.
4
Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.新型丙型肝炎病毒治疗方案的成本效益分析。
Ann Intern Med. 2015 Mar 17;162(6):407-19. doi: 10.7326/M14-1152.
5
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.索磷布韦和来迪帕司韦治疗丙型肝炎病毒在美国的成本效益和预算影响
Ann Intern Med. 2015 Mar 17;162(6):397-406. doi: 10.7326/M14-1336.
6
Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.雷迪帕韦/索磷布韦方案治疗慢性丙型肝炎感染：来自美国工作生产力经济模型的见解。
Hepatology. 2015 May;61(5):1471-8. doi: 10.1002/hep.27757. Epub 2015 Mar 23.
7
Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.丙型肝炎治疗对肝病早期患者的成本效益
Hepatology. 2015 Jun;61(6):1860-9. doi: 10.1002/hep.27736. Epub 2015 Mar 16.
8
Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.用 ledipasvir 和 sofosbuvir 治疗可改善患者报告的结局：来自 ION-1、-2 和-3 临床试验的结果。
Hepatology. 2015 Jun;61(6):1798-808. doi: 10.1002/hep.27724. Epub 2015 Mar 18.
9
Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.全口服来迪派韦/索磷布韦方案治疗慢性丙型肝炎病毒1型感染患者的成本效益
Aliment Pharmacol Ther. 2015 Mar;41(6):544-63. doi: 10.1111/apt.13081. Epub 2015 Jan 26.
10
Systematic review: patient-reported outcomes in chronic hepatitis C--the impact of liver disease and new treatment regimens.系统评价：慢性丙型肝炎患者报告的结局——肝病及新治疗方案的影响
Aliment Pharmacol Ther. 2015 Mar;41(6):497-520. doi: 10.1111/apt.13090. Epub 2015 Jan 23.